Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Breast cancer bone metastases are common and incurable.
• Tumoral integrin β3 (β3) expression is induced by the bone microenvironment and promotes bone colonization.
• The role of β3 in chemotherapy resistance of established bone metastases was unknown.

Purpose of the Study:

• To investigate the functional role of tumoral integrin β3 (β3) in chemotherapy resistance of breast cancer bone metastases.
• To identify mechanisms of β3-mediated chemoresistance.
• To explore therapeutic strategies combining chemotherapy with targeted interventions.

Main Methods:

• Analysis of β3 expression in murine bone metastases and human triple-negative breast cancer patient samples.
• Genetic deletion of β3 in vivo and in vitro.
• Transcriptomic and metabolic analyses (oxygen consumption, ROS generation, protein production).
• Inhibition of mTORC1 pathway.
• Combination therapy with docetaxel and mTORC1 inhibitors, including nanoparticle delivery.

Main Results:

• Increased β3 expression in tumor cells within bone metastases after docetaxel treatment.
• High tumoral β3 expression correlated with worse outcomes in triple-negative breast cancer.
• Genetic deletion of β3 enhanced docetaxel efficacy in vivo, particularly in bone.
• β3-expressing cells exhibit an alternative metabolic response to chemotherapy via mTORC1 signaling.
• Combination therapy with docetaxel and mTORC1 inhibitors synergistically reduced bone metastases.
• Nanoparticle delivery of mTORC1 inhibitor to αvβ3-expressing cells enhanced docetaxel efficacy.

Conclusions:

• Integrin β3 induction by the bone microenvironment promotes chemotherapy resistance through an altered metabolic response.
• Targeting the β3-mediated metabolic pathway with mTORC1 inhibitors, especially via nanotherapy, can overcome chemoresistance.
• This study highlights the importance of the metastatic microenvironment in treatment design and offers novel bone-specific strategies to enhance chemotherapeutic efficacy.